The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo
Speakers' Bureau - Bayer; Lilly; Merck; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo; Dainippon Sumitomo Pharma; Giriad; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yung-Jue Bang
Consulting or Advisory Role - BeiGene; Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hisateru Yasui
Honoraria - Daiichi Sankyo
 
Yoshinori Kawaguchi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
 
Kaku Saito
Employment - Daiichi Sankyo
 
Rita Dalal
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo/Lilly
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Lilly; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)